| Issue Date | Title | Author(s) |
| 1-Jun-2023 | Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. | Pinato, DJ; Li, X; Mishra-Kalyani, P; D'Alessio, A; Fulgenzi, CAM, et al |
| May-2023 | Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials | Fulgenzi, CAM; Scheiner, B; Korolewicz, J; Stikas, C-V; Gennari, A, et al |
| Nov-2022 | Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma | Vithayathil, M; D'Alessio, A; Fulgenzi, CAM; Nishida, N; Schoenlein, M, et al |
| 16-Feb-2022 | Prognostic effect of body mass index in patients with advanced NSCLC treated with chemo-immunotherapy combinations | Cortellini, A; Ricciuti, B; Vaz, VR; Soldato, D; Alessi, JVM, et al |
| 1-Jun-2024 | Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study | Pinato, DJ; D'Alessio, A; Fulgenzi, CAM; Schlaak, AE; Celsa, C, et al |
| Apr-2023 | SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry | Cortellini, A; Tabernero, J; Mukherjee, U; Salazar, R; Sureda, A, et al |
| 14-Jul-2023 | Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer | Cortellini, A; D'Alessio, A; Cleary, S; Buti, S; Bersanelli, M, et al |